Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Fed: Warsh risks and delayed cuts – Commerzbank

Fed: Warsh risks and delayed cuts – Commerzbank

FXStreetFXStreet2026/04/22 11:54
By:FXStreet

Commerzbank economists Bernd Weidensteiner and Christoph Balz assess the implications of Kevin Warsh’s potential appointment as Federal Reserve (Fed) Chair for US monetary policy. They argue that Warsh’s criticism of recent Fed policy and focus on AI-driven disinflation could threaten Fed independence and lead to overly aggressive rate cuts over time, but they still expect the next Fed move only toward year-end.

Warsh, Fed independence and rate outlook

"We are also not quite as optimistic as Warsh that AI will significantly lower inflation. We therefore remain generally skeptical that Warsh can defend the Fed’s independence from Trump. Rather, the central bank is likely to cut interest rates more aggressively than appropriate in the medium term."

"Even if Warsh were to take over as chair soon, it is by no means clear whether the Fed would then comply with Trump’s demand for rapid interest rate cuts. After all, inflation has picked up again in the wake of the war against Iran, so the return of the inflation rate to the 2% target is likely to be further delayed."

"As chairman, Warsh would face major difficulties in securing a majority for an interest rate cut at his first meeting in June. If rates remain unchanged, Warsh would likely very quickly come under the president’s scrutiny, putting him at risk of facing the same difficulties with Trump as Powell did before him."

"We stand by our forecast that the Fed will likely not be able to deliver the next interest rate move until toward the end of the year. After all, Warsh will need some time to assert himself within the Fed."

(This article was created with the help of an Artificial Intelligence tool and reviewed by an editor.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

U.S. non-farm payrolls surge by 165,000 in October, far exceeding expectations! Unemployment rate unexpectedly drops to 4.1%, December rate hike expectations intensify

In October, US non-farm payrolls increased by 165,000, which is 2.5 times the Wall Street median forecast of 65,000 and represents an exceptionally strong deviation of about 5 standard deviations, exceeding the upper limit of all institutional forecast ranges. The unemployment rate unexpectedly fell from 4.2% to 4.1%, while the market had expected it to remain unchanged; average hourly wages also accelerated year-on-year growth to 3.1%. Meanwhile, the previous two months' non-farm payrolls were revised upwards by a total of 84,000. Following the release of the data, the yield on 2-year US Treasury bonds rose by 7 basis points, and the pricing of the probability of a Fed rate hike in December climbed to 70%.

华尔街见闻•2026/11/06 15:01

AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

The valuation range discussed by potential investors has been lowered from the previous high of $2 trillion to between $1.2 trillion and $1.3 trillion, and some strategists have even suggested going below $1 trillion to ensure safety. In the face of significant market volatility and financial concerns such as quarterly losses, Anthropic is facing tough decisions, including a discounted valuation, reducing the size of the offering, or postponing the listing.

华尔街见闻•2026/11/06 13:42
AI Sell-off Hits Anthropic IPO, Potential Valuation Expected to Drop to $1.2–1.3 Trillion

Moderna Q3 revenue up 29% year-on-year, far exceeding expectations, raises full-year revenue growth guidance to 15%-25% | Earnings Report Insight

Moderna's Q3 revenue increased by 29% year-on-year to $1.31 billion, with profits significantly exceeding expectations. The company raised its 2026 revenue growth guidance to 15%-25%. The ramp-up of next-generation COVID-19 and flu vaccines, along with international market expansion, has driven performance improvement. Phase III data for the personalized cancer vaccine has also shown positive progress. The company is simultaneously advancing cost reduction and pipeline R&D, with year-end cash expectations significantly raised.

华尔街见闻•2026/11/06 13:23